Stifel Nicolaus Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA)

Stifel Nicolaus initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKAFree Report) in a research note released on Friday, Marketbeat Ratings reports. The firm issued a buy rating and a $49.00 price objective on the stock.

A number of other research analysts also recently issued reports on ORKA. TD Cowen started coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They set a buy rating on the stock. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research report on Friday, September 13th. They issued a buy rating and a $40.00 price objective for the company. HC Wainwright assumed coverage on Oruka Therapeutics in a research note on Monday, October 7th. They issued a buy rating and a $45.00 price target on the stock. Leerink Partners started coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They set an outperform rating and a $44.00 target price for the company. Finally, Lifesci Capital began coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set an outperform rating and a $41.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus target price of $43.17.

Read Our Latest Report on Oruka Therapeutics

Oruka Therapeutics Stock Up 6.5 %

Shares of Oruka Therapeutics stock opened at $27.74 on Friday. The firm has a market capitalization of $33.57 million, a PE ratio of -4.62 and a beta of 0.89. Oruka Therapeutics has a 1-year low of $18.72 and a 1-year high of $53.88.

Oruka Therapeutics (NASDAQ:ORKAGet Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($25.92) EPS for the quarter. As a group, analysts anticipate that Oruka Therapeutics will post -1.62 EPS for the current year.

About Oruka Therapeutics

(Get Free Report)

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.

Recommended Stories

Analyst Recommendations for Oruka Therapeutics (NASDAQ:ORKA)

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.